PART 4: DIABETIC NEPHROPATHY
Books, Book Chapters, Guidelines, Reports, Proceedings
1.
Clinical Practice Guidelines: Diabetic nephropathy. Kuala Lumpur: Ministry of Health, Malaysia, 2004. http://www.acadmed.org.my/view_file.cfm?fileid=271Dissertations, Theses
1. Parameswary AM. The therapeutic potential of antisense oligodeoxynucleotide to transforming growth factor beta-1 in diabetic nephropathy. PhD Thesis, University of Malaya, 2007.
2. Suhaidarwani, AH. .Prevalence of vitamin D deficiency and the effects of 1-alpha calcidol on inflammation and proteinuria in type 2 diabetic patients with nephropathy. MMed Dissertation, Universiti Sains Malaysia, 2012.
Reviews, Editorials, Commentaries
Original research
1. Abougalambou SSI, Abougalambou ASI. Prevalence and risk factors of microalbuminuria in type 2 diabetes mellitus outpatients at University Sains Malaysia Hospital. Diabetes Metab Syndr 2013;7(2):64-7
2.
Chan JCN, Wat NMS, So WY, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. Diabetes Care2004;27(4):874-9
http://care.diabetesjournals.org/content/27/4/874.full.pdf
3. Chong YB, Keng TC, Tan LP, et al. Clinical predictors of non-diabetic renal disease and role of renal biopsy in diabetic patients with renal involvement: a single centre review. Ren Fail 2012;34(3):323-8
4. ESRD Incidence Study Group, Stewart JH, McCredie MR, et al. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrol Dial Transplant 2006;21(8):2178-83
5.
Faradianna E. L, Norhashimah AS, Aziz al-Safi I, et al. Gene expression profiling in ethnic Malays with type 2 diabetes mellitus, with and without diabetic nephropathy. J Nephrol 2011;24(6):778-89http://www.sin-italy.org/web%5Ceventi%5CSIN%5Carchivio%5Cjn
%5C2011%5Cjnephrol_2011_6%5CJN_2011_6_778-789_WANMOHAMUD.pdf
6. Fathimah M, Alicezah MK, Thevarajah M. Neutrophil Gelatinase-Associated Lipocalin (NGAL): an early marker for diabetic nephropathy. Int J Diabetes Dev Ctries 2012;32(1):19-24
7.
Jaime JJ, Sekaran M, Chan SP. Null association between ACE gene I/D polymorphism and diabetic nephropathy among multiethnic Malaysian subjects. Indian J Hum Genet 2010;16(2):78-86 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC29559568.
Kong NC, Chia YC, Khalid AK, et al. Microalbuminuria prevalence study in hypertensive type 2 diabetic patients in Malaysia. Med J Malaysia 2006;61(4):457-65http://www.e-mjm.org/2006/v61n4/Microalbuminuria.pdf.
9.
Menon R, Mohd Noor FS, Draman CR, et al. A retrospective review of diabetic nephropathy patients during referral to the sub-urban nephrology clinic. Saudi J Kidney Dis Transpl 2012;23(5):1109-14http://www.sjkdt.org/temp/SaudiJKidneyDisTranspl2351109-2002252_053342.pdf
10. Munisamy S, Kamaliah MD, Suhaidarwani AH, et al. Impaired microvascular endothelial function in vitamin D-deficient diabetic nephropathy patients. J Cardiovasc Med (Hagerstown) 2013;14(6):466-71
11. Norbanee THT, Kamaliah MD, Ismail AA. Prevalence and risk factors for microalbuminuria in patients with type 2 diabetes mellitus in north-east Malaysia. International Medical Journal (Tokyo) 2003;10:261-6
12.
Norhashimah AS, Witasp A, Wan Nazaimoon WM, et al. Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population. J Diabetes Res2013;2013:298019
http://www.hindawi.com/journals/jdr/2013/298019/
14.
Ooi CG, Haizee HN, Kando DV, et al. Diabetes mellitus in a Malaysian teaching hospital: prevalence of diabetes mellitus and frequency of testing for hypercholesterolaemia, proteinuria and HbA1c. Med J Malaysia 2002;57(2):195-200http://www.e-mjm.org/2002/v57n2/Diabetes_Mellitus.pdf
15.
Pavai S, Chan SP. Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol 2010;32(1):43-7 http://www.mjpath.org.my/2010.1/Urinary_type_IV_collagen.pdf.16.
Reddy SC, Kihn YM, Nurjahan MI, et al. Retinopathy in type 2 diabetic patients with microalbuminuria.Nepal J Ophthalmol 2013;5(1):69-74
http://nepjol.info/index.php/NEPJOPH/article/view/7830/6389.
17. Sharmini S, Uiterwaal CS, Jamaiyah H, et al. Renal impairment and all-cause mortality in cardiovascular disease: effect modification by type 2 diabetes mellitus. Eur J Clin Invest 2013;43(2):198-207
18.
Umi A, Md. Idris MN, Osman A. Risk factors for diabetic nephropathy among non-insulin dependent patients who attended City Hall's Staff Clinic in Kuala Lumpur. Malaysian Journal of Public Health Medicine2001;1:16-21
http://www.mjphm.org.my/mjphm/journals/Volume%201%20:%202001/16-21.pdf
19.
Wong JS. Proteinuria in diabetic patients in a primary health care setting in Sarawak. Med J Malaysia2005;60(2):146-50
http://www.e-mjm.org/2005/v60n2/Proteinuria.pdf
20.
Wong KS, Hwang S, Han DC, et al. Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective. Nephrology (Carlton) 2005;10(5):520-4http://www.pkdiet.com/pdf/losartanreducesesrd.pdf
21.
Yeo CK, Hapizah MN, Khalid AK, et al. The comparison of QT dispersion and 24 hour ambulatory blood pressure monitoring amongst diabetic patients with and without microalbuminuria. Med J Malaysia2004;59(2):185-9
http://www.e-mjm.org/2004/v59n2/Diabetic_Patients.pdf Case reports
